Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment
- 31 May 2011
- journal article
- review article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 178 (5), 1940-1948
- https://doi.org/10.1016/j.ajpath.2010.12.057
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 45 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Are RAS mutations predictive markers of resistance to standard chemotherapy?Nature Reviews Clinical Oncology, 2009
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996